

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/088312 A2

(51) International Patent Classification⁷: **G01N 33/533**

(74) Agent: **NOVAGRAAF PATENTS LIMITED**; The Crescent, 54 Blossom Street, York YO24 1AP (GB).

(21) International Application Number:

PCT/GB2004/001418

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0307559.5 2 April 2003 (02.04.2003) GB
60/465,807 28 April 2003 (28.04.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF NOTTINGHAM** [GB/GB]; University Park, Nottingham NG7 2RD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GEORGE, Michael** [GB/GB]; School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD (GB). **HILL, Stephen, John** [GB/GB]; Institute of Cell Signalling, C Floor, Medical School, Queen's Medical Centre, Nottingham NG7 2UH (GB). **KELLAM, Barrie** [GB/GB]; School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham NG7 2RD (GB). **MIDDLETON, Richard, John** [GB/GB]; School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham NG7 2RD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **FLUORESCENTLY TAGGED LIGANDS**

(57) **Abstract:** Library comprising a plurality of tagged non-peptide ligands of formula (I): (Lig J_L)_m L(J_T Tag)_m (J_TL(J_LLig))_p including and salts thereof comprising one or a plurality of same or different ligand moieties Lig each linked to a one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality J_T and J_L wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter; L is a single bond or is any linking moiety selected from a heteroatom such as N, O, S, P, branched or straight chain saturated or unsaturated, optionally heteroatom containing, C₁₋₆₀₀ hydrocarbyl and combinations thereof, which may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300; Tag is any known or novel tagging substrate; m are each independently selected from a whole number integer from 1 to 3; p is 0 to 3 characterised in that linking is at same or different linking sites in compounds comprising different Lig, J_L, L J_T and/or - Tag and is at different linking sites in compounds comprising same Lig, J_L, L J_T and/or - Tag; process for the preparation thereof; process for the preparation of a library compound of formula (I) or a precursor of formula (IV); method for selecting a compound of formula (I) from a library thereof; compound of formula (I) associated with information relating to its pharmacological properties; a novel compound of formula (I) or precursor of formula (IV); uses thereof; methods for binding or inhibition therewith; use of a fluorescent target therewith; a modified cell surface GPCR and cells expressing the same; and a kit comprising a compound of formula (I) and a target therefor.



WO 2004/088312 A2